A diagnostic dilemma: A rare case of an ovarian carcinoma with signet ring cells hidden behind a substantial dermatomyositis ABSTRACT Dermatomyositis (DM) is a malignancy-associated inflammatory connective tissue disease which involves muscles and skin. It accompanies many cancer types. Herein, we aimed to present a 42-year-old patient with primary signet ring cell ovarian carcinoma which has not been seen hitherto. Presentation with DM induces rapid and aggressive progression and emphasizes the importance of more comprehensive malignancy screening in these patients.
INTRODUCTION
Dermatomyositis (DM) is an inflammatory connective tissue disease. It is associated frequently with cancer. It is more frequently accompanied by lung, breast, ovarian, gastric, and rectal cancers. [1] Primary signet cell ovarian carcinomas are very rarely seen, and only three cases of primary carcinoma have been reported. [2] Herein, we wanted to present previously unseen case with advanced stage primary ovarian carcinoma characterized with DM.
CASE REPORT
A 42-year-old gravida 2, parity 2 premenopausal patient applied with muscle weakness, loss of appetite, abdominal distension, shortness of breath, progressive difficulty in swallowing, and skin rash. The patient had not any gynecologic complaint. On physical examination, periorbital heliotrope rash, photosensitive erythematous face, and periorbital edema were observed [ Figure 1a ]. Bilaterally, Gottron's papules were observed on finger joints, proximal interphalangeal joints, and periungual spaces [ Figure 1b -d]. Gower's signs were detected bilaterally on shoulders, arms, and legs. Speculum examination was unremarkable, pelvic examination detected diffuse distension, and bilateral adnexes could not be palpated. On laboratory assessments, higher aspartate aminotransferase (393 IU/L), alanine aminotransferase (131 IU/L), lactate dehydrogenase (968 U/L), amylase (93 U/L), lipase (89 U/L), total creatinine kinase (5009 U/L), and creatine kinase-muscle/brain (128 U/L) values were detected. Among tumor markers, higher CA125 (4214 ng/ml) levels were detected while other tumor markers were not observed. Myopathy was implied by electromyography results. On panendoscopy, any suspect lesion suggesting malignancy was not encountered. Mammography results were within normal limits. On transvaginal sonography, bilateral adnexal tumors and prominent ascites were detected. On 18 F-fluorodeoxyglucose-positron emission tomography-computed tomography, heterogeneous hypermetabolic lesions measuring 33 mm × 39 mm on the right and 23 mm × 27 mm (maximum standardized uptake value: 4) on the left adnexes were detected [ Figure 2a ]. Multiple metastatic foci on the liver and abdomen, peritoneal carcinomatosis, massive ascites, and pleural effusion in the right hemithorax were Therapeutic pleural fluid sampling was performed based on dyspneic symptoms, and immunohistochemical analysis of the malignant cytology revealed carcinoembryonic antigen positivity which also indicated epithelial origin while CA125 positivity, negative GIS screening, and other imaging test results were found to be compatible with primary ovarian signet ring cell carcinoma [ Figure 3c -f]. Weekly chemotherapy treatment was planned for the patient whose diagnosis was accepted as metastatic primary signet ring cell ovarian cancer. Despite supportive treatment, the patient's breathlessness increased and overall condition deteriorated. Besides, her liver enzyme levels increased progressively and her clinical health state worsened while her symptomatic treatment maintained, so she was monitored under intensive care unit. The patient developed sepsis and multiple organ failure during her monitorization. She experienced cardiopulmonary arrest on 7 days of her intensive care unit stay and exited.
DISCUSSION
DM is chronic systemic autoimmune muscle disease. The prevalence of malignancy in DM patients was reported to range between 10% and 60%. [3] Our case basically presented with symptoms of DM and advanced stage ovarian cancer accompanied DM. Although specific treatment was initiated for DM and detailed concurrent screening for malignancy was performed, rapid clinical progression of the disease with poor prognosis developed.
According to various authors, DM presents with serous ovarian carcinoma (Bjørnhart et al.) , adenosquamous carcinoma (Rodríguez Moguel et al.) , and transitional cell carcinoma (Hagman et al.) . [4] [5] [6] We did not encounter any literature study which reported a patient with DM presented with primary signet ring cell ovarian carcinoma.
Primary signet ring cell ovarian tumors are very rarely seen. Up to now, a total of 17 cases including benign tumors have been reported, and in only four of them, signs of malignancy as mitotic activity and pleomorphism have been observed. [7] [8] [9] A multiple number of studies have been performed to determine risk factors for the development of malignancy. In a study performed by Fang et al. in accordance with our case, age of onset was >40 years, and a positive correlation was detected between advanced age (>40 years) at onset, heliotrope rash, Gottron's sign, dysphagia, and risk of malignancy in compliance with the results of our study. [10] A limited number of data exist concerning prognosis of primary signet ring cell ovarian carcinomas. The massive and aggressive proliferation of signet ring cells also effects prognosis adversely. [8] CONCLUSION Specific symptomatic treatment should be provided for DM patients with advanced age, and meantime, a comprehensive malignancy screening should be performed. It should not be forgotten that in these patients, neoplastic process may progress to advanced stage at a higher rate. In rarely seen primary ovarian signet ring cell carcinomas with poor prognosis, the risk of mortality should be tried to be reduced using an optimal treatment plan.
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